{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:21:23Z","timestamp":1779290483057,"version":"3.51.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec>\n            <jats:title>Study Design:<\/jats:title>\n            <jats:p>Retrospective analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary of Background Data:<\/jats:title>\n            <jats:p>Recent advancements in systemic treatment of lung cancer have significantly improved the survival of patients with certain histolopathologic and molecular subtypes. Existing prognostic scores do not account for this and patients with lung cancer spinal metastases are grouped together as poor prognostic candidates, and consequently, some may be inappropriately denied palliative spine surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>The objective of the study was to study whether the expected survival in patients with lung cancer spinal metastases is affected by histolopathologic and molecular subtypes in the context of modern systemic therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>We retrospectively reviewed all patients with histologically confirmed lung cancer treated for spinal metastases at our institution between 2001 and 2012. Patients\u2019 demographics, histopathologic details, treatment modalities, and survival data were collected. The primary outcome was survival from time of spinal metastases diagnosis. The Cox regression analysis was used to evaluate the influence of tumor histology, molecular profile and treatment modality on survival. The Kaplan-Meier survival analysis was conducted to compare lung cancer subtypes, as well as various treatment regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Out of 180 patients, 51 underwent surgery for spinal metastases. Female sex (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.019), absence of palsy (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.023), good Karnofsky performance scores (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001), and non\u2013small cell lung cancer (NSCLC) (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.002) were favorable prognostic factors. Patients who received systemic therapy, including tyrosine kinase inhibitors, platinum doublet chemotherapy, or both showed increased survival (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.01). The median survival time was 2.40 months [95% confidence interval (CI), 2.13\u20132.68] in the small cell lung cancer cohort, with no patients surviving past a year; 5.10 months (95% CI, 3.78\u20136.41) in the NSCLC cohort, with 25.9% 1-year survival; and 13.3 months (95% CI, 2.26\u201324.40) in adenocarcinoma patients who received both tyrosine kinase inhibitors and platinum doublet therapy, with 50.0% 1-year survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>NSCLC, systemic therapy, female sex, absence of palsy and good Karnofsky performance scores are all independent favorable prognostic factors for patients with lung cancer spinal metastases. These should be routinely considered during prognostication.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bsd.0000000000000475","type":"journal-article","created":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T13:09:37Z","timestamp":1522415377000},"page":"E1-E7","source":"Crossref","is-referenced-by-count":7,"title":["The Influence of Histologic Subtype in Predicting Survival of Lung Cancer Patients With Spinal Metastases"],"prefix":"10.1097","volume":"31","author":[{"given":"Naresh","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, National University Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly-Anne","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, National University Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiong Hao","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, National University Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aye S.","family":"Zaw","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, National University Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwee Weng Dennis","family":"Hey","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, National University Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, National University Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Stone","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine, St. Vincent\u2019s Hospital, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230831","first-page":"553","article-title":"New strategies in immunotherapy for non-small cell lung cancer","volume":"4","author":"Carrizosa","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"suppl 5","key":"R2-20230831","first-page":"S579","article-title":"Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer","volume":"5","author":"Savas","year":"2013","journal-title":"J Thorac Dis"},{"key":"R3-20230831","doi-asserted-by":"crossref","first-page":"E1015","DOI":"10.1097\/BSD.0000000000000400","article-title":"Metastatic spine tumor surgery: a comparative study of minimally invasive approach using percutaneous pedicle screws fixation versus open approach","volume":"43","author":"Kumar","year":"2017","journal-title":"Clin Spine Surg"},{"key":"R4-20230831","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/BRS.0000000000001279","article-title":"Evaluation of scoring systems and prognostic factors in patients with spinal metastases from lung cancer","volume":"41","author":"Tan","year":"2016","journal-title":"Spine"},{"key":"R5-20230831","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0140-6736(05)66954-1","article-title":"Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial","volume":"366","author":"Patchell","year":"2005","journal-title":"Lancet"},{"key":"R6-20230831","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3322\/CA.2007.0016","article-title":"Spinal extradural metastasis: review of current treatment options","volume":"58","author":"Bartels","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"R7-20230831","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/foc.2001.11.6.2","article-title":"Metastatic spinal tumors","volume":"11","author":"Heary","year":"2001","journal-title":"Neurosurg Focus"},{"key":"R8-20230831","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1007\/s00586-008-0763-1","article-title":"Predictive value of seven preoperative prognostic scoring systems for spinal metastases","volume":"17","author":"Leithner","year":"2008","journal-title":"Eur Spine J"},{"key":"R9-20230831","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1302\/0301-620X.95B2.29323","article-title":"The Oswestry Risk Index: an aid in the treatment of metastatic disease of the spine","volume":"95-B","author":"Balain","year":"2013","journal-title":"Bone Joint J"},{"key":"R10-20230831","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.brs.0000180401.06919.a5","article-title":"A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis","volume":"30","author":"Tokuhashi","year":"2005","journal-title":"Spine (Phila Pa 1976)"},{"key":"R11-20230831","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00007632-200102010-00016","article-title":"Surgical strategy for spinal metastases","volume":"26","author":"Tomita","year":"2001","journal-title":"Spine (Phila Pa 1976)"},{"key":"R12-20230831","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1007\/s00586-015-4112-x","article-title":"Are we ready for the use of intraoperative salvaged blood in metastatic spine tumour surgery?","volume":"25","author":"Kumar","year":"2016","journal-title":"Eur Spine J"},{"key":"R13-20230831","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ijrobp.2014.07.051","article-title":"An easy tool to predict survival in patients receiving radiation therapy for painful bone metastases","volume":"90","author":"Westhoff","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R14-20230831","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/BRS.0b013e318294835b","article-title":"Prognosis in patients with symptomatic metastatic spinal cord compression: survival in different cancer diagnosis in a cohort of 2321 patients","volume":"38","author":"Morgen","year":"2013","journal-title":"Spine"},{"key":"R15-20230831","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"R16-20230831","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/BRS.0b013e3181e8f7f8","article-title":"Actual and predicted survival time of patients with spinal metastases of lung cancer: evaluation of the robustness of the Tokuhashi score","volume":"36","author":"Hessler","year":"2011","journal-title":"Spine"},{"key":"R17-20230831","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/01.brs.0000222146.91398.c9","article-title":"Prognostic factors for patients with spinal metastases from lung cancer","volume":"31","author":"Ogihara","year":"2006","journal-title":"Spine"},{"key":"R18-20230831","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/BRS.0b013e31822bd6b0","article-title":"Predictive value of Tokuhashi scoring systems in spinal metastases, focusing on various primary tumor groups: evaluation of 448 patients in the Aarhus spinal metastases database","volume":"37","author":"Wang","year":"2012","journal-title":"Spine (Phila Pa 1976)"},{"key":"R19-20230831","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/BRS.0b013e3182011f84","article-title":"Survival analysis of 254 patients after manifestation of spinal metastases: evaluation of seven preoperative scoring systems","volume":"36","author":"Wibmer","year":"2011","journal-title":"Spine (Phila Pa 1976)"},{"key":"R20-20230831","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00586-009-1252-x","article-title":"Review of metastatic spine tumour classification and indications for surgery: the consensus statement of the Global Spine Tumour Study Group","volume":"19","author":"Choi","year":"2010","journal-title":"Eur Spine J"},{"key":"R22-20230831","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrclinonc.2013.22","article-title":"Surgery for NSCLC in the era of personalized medicine","volume":"10","author":"Mitsudomi","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"R23-20230831","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.athoracsur.2003.11.021","article-title":"Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002","volume":"78","author":"Visbal","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"R24-20230831","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/95.5.362","article-title":"Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial","volume":"95","author":"Gridelli","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R25-20230831","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"R26-20230831","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lungcan.2014.01.009","article-title":"International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women","volume":"84","author":"Lortet-Tieulent","year":"2014","journal-title":"Lung Cancer"}],"container-title":["Clinical Spine Surgery: A Spine Publication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01933606-201802000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T19:10:54Z","timestamp":1693509054000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01933606-201802000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bsd.0000000000000475","relation":{},"ISSN":["2380-0186"],"issn-type":[{"value":"2380-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}